Colt Ventures

Alterome Therapeutics is a biotechnology company focused on precision oncology, dedicated to developing targeted therapeutics that specifically address validated oncogenic drivers in cancer. The firm aims to discover and create alteration-specific therapies that provide hope and improved treatment options for individuals affected by cancer. By concentrating on high-value oncogenic alterations, Alterome Therapeutics seeks to enhance the effectiveness of cancer treatments and support healthcare providers in their efforts to combat the disease.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Alterome Therapeutics is a biotechnology company focused on precision oncology, dedicated to developing targeted therapeutics that specifically address validated oncogenic drivers in cancer. The firm aims to discover and create alteration-specific therapies that provide hope and improved treatment options for individuals affected by cancer. By concentrating on high-value oncogenic alterations, Alterome Therapeutics seeks to enhance the effectiveness of cancer treatments and support healthcare providers in their efforts to combat the disease.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

EBY, LLC is a New York-based company that specializes in women's underwear and lingerie, offering a range of products in various shapes and sizes through an online retail platform. Founded in 2017, EBY operates on a membership model that includes a subscription service for regular delivery of its intimate apparel. The company distinguishes itself by promoting underwear as a tool for empowerment, committing 10% of its net sales to the Seven Bar Foundation to support women in overcoming poverty through microfinance loans. These loans, which can range from $80 to $7,000, enable women to start or expand their businesses, fostering self-sufficiency and breaking the cycle of poverty. EBY's innovative approach not only enhances the shopping experience with patented technology that prevents sliding and riding but also aims to create lasting social impact through its commitment to empowering women.

Rumble Inc. is a video management platform based in Toronto, Canada, established in 2013. It serves as an open video-sharing system for publishers and creators, allowing users to watch, share, and engage with videos. The platform enables users to upload their own content, including text, images, and videos, while also providing a rights management system to ensure proper licensing. Users can subscribe to channels to keep updated on new content and can access both on-demand videos and live streams from creators. The majority of Rumble's revenue is generated from the United States.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

ReCode Therapeutics is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a unique non-viral lipid nanoparticle platform that facilitates the precise delivery of nucleic acid and protein payloads to specific organs and tissues, enhancing the effectiveness of genetic therapies. This selective organ targeting (SORT) technology allows for the administration of corrective or disease-modifying treatments beyond the liver, addressing the challenges faced by traditional gene therapy methods. By harnessing these innovative techniques, ReCode Therapeutics aims to provide new therapeutic options for patients suffering from rare and life-limiting respiratory diseases.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Bonti, Inc. is a biotechnology company based in Newport Beach, California, specializing in the development of neurotoxin products for both aesthetic and therapeutic applications. Founded in 2015 and previously known as Endurance Biotech, Bonti focuses on botulinum neurotoxin serotype E, with its key products including EB-001A for aesthetic use and EB-001T for therapeutic purposes. The company's innovations aim to address unmet medical needs, particularly in treating muscle hyperactivity, which is a significant cause of musculoskeletal pain in various patient populations. Bonti's neurotoxin offers a long-acting, non-opioid local muscle relaxant option, designed to minimize the side effects associated with existing treatments. As of October 2018, Bonti operates as a subsidiary of Allergan plc.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.